| Methods |
RCT.
Double‐masked until 18 months.
Active controlled. |
| Participants |
44 participants, all Caucasian.
Inclusion criteria: POAG with IOP at least 24 mmHg, early glaucomatous field defect.
Exclusion criteria: diabetes mellitus, other local treatment or systemic medication with beta‐blockers, previous laser treatment or glaucoma surgery. |
| Interventions |
Timolol 0.5% twice daily.
Betaxolol 0.5% twice daily. |
| Outcomes |
Change of visual field mean sensitivity and mean defect. |
| Notes |
Allocation concealment deemed likely, based on double‐masked design.
4 years follow up.
Double‐masked until 18 months, thereafter open label.
15 drop‐outs (8 timolol: 1 local and 1 systemic side effect; 7 betaxolol: 2 local side effects). |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
